LGVN — Longeveron Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1721484 ·
Last close
$2.11
Market Cap
$6.83M
52W High
$12.30
52W Low
$1.31
ADV30
92,243
Next earnings
2026-11-12
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 115,000 71,000 -7,197,000 -6,135,000 12,015,000 7,245,000 7,305,000
Jun 2026 287,000 182,000 -6,171,000 -6,073,000 15,487,000 10,077,000 5,085,000
Mar 2026 398,000 264,000 -4,775,000 -4,736,000 21,210,000 15,758,000 5,183,000
Dec 2025 365,000 257,000 -5,399,000 -5,444,000 10,261,000 4,661,000 4,586,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-20,374,000
Investing CF
$-305,000
Financing CF
$20,422,000
CapEx
$-305,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.10
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-143,120,000
Inventory
—
Receivables
$65,000
ST Investments
—
EBIT TTM
$-23,655,000
Pretax Income TTM
$-23,474,000
Interest Exp TTM
—
Analysts
2

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,187,000
EBITDA
$-22,440,000
Free Cash Flow
$-11,603,375
Enterprise Value
$-27,051
Total Cash
$10,077,000
Total Debt
$581,000
Shares Out
3,234,935
Trailing EPS
$-7.95
Book Value
$2.48
ROE
-203.6%
ROA
-90.9%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 1,199,000 -23,287,000 -22,704,000 10,261,000 4,586,000 5,675,000 -18,645,000
Dec 2024 2,392,000 -16,522,000 -15,973,000 25,558,000 3,671,000 21,887,000 -13,868,000
Dec 2023 709,000 -21,029,000 -21,413,000 12,078,000 5,337,000 6,741,000 -19,002,000
Dec 2022 1,222,000 -18,043,000 -18,835,000 27,413,000 6,910,000 20,503,000 -13,969,000

TTM Snapshot

Revenues TTM
$1,187,000
NetIncome TTM
$-23,474,000
OpCashFlow TTM
—
Assets (Latest)
$15,487,000
Forward EPS
$-1.53

Peers — same industry

TickerNameMarket CapLastDaily %
CVKD Cadrenal Therapeutics, Inc. $6.71M $1.88 —
MBRX Moleculin Biotech, Inc. $6.96M $6.83 —
IMRN Immuron Ltd $7.03M $0.87 —
XCUR EXICURE, INC. $7.07M $1.08 —
TPST Tempest Therapeutics, Inc. $6.54M $0.33 —

News headlines (Yahoo Finance, 1h cache)

LGVN Has Multiple Options
2026-11-13 11:01 · Yahoo
Longeveron Announces 2026 Third Quarter Financial Results and Provides Business Update
2026-11-12 21:54 · Yahoo
Longeveron Announces Engagement of Lucid Capital Markets
2026-10-28 13:15 · Yahoo
Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)
2026-10-26 13:15 · Yahoo
Longeveron to Participate in Three Longevity/Aging Investment Conferences
2026-09-30 20:05 · Yahoo
LGVN Posts Disappointing Trial Results
2026-09-17 11:14 · Yahoo
Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)
2026-09-16 21:27 · Yahoo
Longeveron to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-03 13:15 · Yahoo
Longeveron Announces 1-for-10 Reverse Stock Split
2026-08-24 20:05 · Yahoo
Longeveron (LGVN) Q2 2026 Earnings Call Transcript
2026-08-19 21:58 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.